Last reviewed 2026-04-20 · How we verify

Norpropandrolate (BOLANDIOL DIPROPIONATE)

Phase 2 active Small molecule

Norpropandrolate (generic name: BOLANDIOL DIPROPIONATE) is a bolandiol drug. It is currently in Phase 2 development.

Norpropandrolate is believed to work by interacting with the body's hormonal system, although its exact mechanism of action is unknown.

Norpropandrolate, also known as bolandiol dipropionate, is a small molecule drug in the bolandiol class. Its exact target and mechanism of action are unknown, but it is believed to work by interacting with the body's hormonal system. Norpropandrolate is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, it is not currently available for clinical use.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BOLANDIOL DIPROPIONATE
Drug class	bolandiol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's hormones as a complex system of messengers that help different parts of your body work together. Norpropandrolate is thought to affect this system in some way, although the exact details are not yet understood. This could potentially lead to changes in how your body functions, but more research is needed to determine the specifics.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Norpropandrolate CI brief — competitive landscape report
Norpropandrolate updates RSS · CI watch RSS

Frequently asked questions about Norpropandrolate

What is Norpropandrolate?

Norpropandrolate (BOLANDIOL DIPROPIONATE) is a bolandiol drug.

How does Norpropandrolate work?

Norpropandrolate is believed to work by interacting with the body's hormonal system, although its exact mechanism of action is unknown.

What is the generic name of Norpropandrolate?

BOLANDIOL DIPROPIONATE is the generic (nonproprietary) name of Norpropandrolate.

What drug class is Norpropandrolate in?

Norpropandrolate belongs to the bolandiol class. See all bolandiol drugs at /class/bolandiol.

What development phase is Norpropandrolate in?

Norpropandrolate is in Phase 2.

Drug class: All bolandiol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing